Assessment of multiple drug resistance and sensitivity to helicobacter pylori in patients with peptic ulcer disease

Helicobacter pylori [H.pylori] is implicated in acute superficial gastritis, chronic atrophic gastritis, gastric carcinoma and MALT [Mucosa Associated Lymphoid Tissue] associated lymphoma. Prevalence of H. pylori antibiotic resistance is increasing and affect the efficacy of treatment. Our aim was to improve infected patients with new generations of antibiotics. 88 peptic ulcer patients recruited from gastroenerology and endoscopy unit at Suez Canal University, 5 gastric biopsies were taken from each and were examined for H. pylori by histopathology, rapid urease test and culture. Antibiotic susceptibility test was performed to: metronidazole, clarithromycin, amoxicillin, amoxicillin calvulanic acid, levofloxacin, tetracycline, ciprofloxacin, ofloxacin, ceftriaxone, cefoperazone and ceftazidime. Night-two% were positive for H. pylori, while 20% of the studied population were positively cultured .The results of antibiotic sensitivity were:100% of patients were sensitive to clindamycin, 87.5% sensitive to erythromycin, 68.8% sensitive to amoxicillin and levofloxacin, 50% sensitive to azithromycin and tetracycline, 25% sensitive to clarithromycin and 18.8% sensitive to amoxicillin and cavulanic acid. H. pylori resistance towards different antibiotics has increased. new promising results regarding clindamycin and erythromycin

Impact of Interleukin-28B gene polymorphism [rs12979860] on Egyptian patients infected with hepatitis C virus genotype-4

Single nucleotide polymorphisms [SNPs] in the Interleukin [IL]-28B gene, namely rs12979860, could predict response to pegylated interferon-alpha-ribavirin [PR] therapy in hepatitis C virus genotype 1 [HCV-1]-infected patients. A similar role was investigated in a case-control study conducted on 93 Egyptian patients chronically infected with HCV-4 in comparison to 22 individuals with spontaneous HCV clearance and 70 healthy volunteers. The homozygous C allele genotype [CC] was associated with sustained viral response [SVR] to therapy compared with the homozygous T allele genotype [TT] and the heterozygous genotype [CT]. In the SVR group, the response rate was statistically significantly higher in CC genotypes [58.6%] compared with CT/TT [20.3%]. There was no correlation between SVR patients' genotypes and early response to therapy or HCV baseline viral load. Our findings describe how IL-28B SNP genotyping may guide appropriate selection of HCV-4-infected patients for PR therapy. We underscore IL28B genotyping as a tool that might increase PR cost-benefit in Egypt